There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type | HazMat fee for 500 gram (Estimated) |
Excepted Quantity | USD 0.00 |
Limited Quantity | USD 15-60 |
Inaccessible (Haz class 6.1), Domestic | USD 80+ |
Inaccessible (Haz class 6.1), International | USD 150+ |
Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |
Structure of Doxercalciferol
CAS No.: 54573-75-0
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Doxercalciferol is a synthetic vitamin D2 analog, suppressing parathyroid synthesis and secretion, used to treat secondary hyperparathyroidism and metabolic bone disease.
Synonyms: 1.alpha.-Hydroxyvitamin D2; 1-hydroxy Vitamin D2; Doxercalciferol. 1-hydroxy Vitamin D2
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 54573-75-0 |
Formula : | C28H44O2 |
M.W : | 412.65 |
SMILES Code : | C=C1[C@H](C[C@@H](C/C1=C/C=C2[C@]3([C@@](C)([C@H](CC3)[C@@H](/C=C/[C@@H](C(C)C)C)C)CCC/2)[H])O)O |
Synonyms : |
1.alpha.-Hydroxyvitamin D2; 1-hydroxy Vitamin D2; Doxercalciferol. 1-hydroxy Vitamin D2
|
MDL No. : | MFCD00871065 |
GHS Pictogram: |
![]() |
Signal Word: | Danger |
Hazard Statements: | H300 |
Precautionary Statements: | P264-P301+P310 |
Class: | 6.1 |
UN#: | 2811 |
Packing Group: | Ⅲ |
In Vitro:
Concentration | Treated Time | Description | References |
N2a wt cells | 100 nM | 18 hours | Doxercalciferol significantly increased Aβ degradation to 158.2%. | PMC5751363 |
SH-SY5Y wt cells | 100 nM | 24 hours | Doxercalciferol significantly reduced β-secretase activity to 77.3%. | PMC5751363 |
SH-SY5Y APP695 overexpressing cells | 100 nM | 24 hours | Doxercalciferol significantly reduced total Aβ level to 70.9%. | PMC5751363 |
Huh7 cells | 1.98 ± 1.30 μmol/L (EC50) | 6 days | To evaluate the inhibitory effect of Doxercalciferol on SFTSV-induced cytopathic effect (CPE), results showed dose-dependent protection against CPE. | PMC11738768 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
ICR suckling mice | Lethal SFTSV infection model | Intraperitoneal injection | 0.3 or 0.15 μg/kg | Daily for 8 days | To evaluate the therapeutic effect of Doxercalciferol on SFTSV-infected ICR suckling mice, results showed increased survival rates (40% protection). | PMC11738768 |
LHβ-Tag transgenic mice | Transgenic retinoblastoma model | Oral gavage | 0.1, 0.3, 0.5, or 1.0 µg/day | Five times per week for 5 weeks | To determine the effectiveness of 1α-OH-D2 in inhibiting retinoblastoma and evaluate its toxicity. Results showed significantly smaller tumor areas in all treatment groups compared to controls (P <.02), but no dose-dependent response curve. Higher mortality was observed in the 0.5 and 1.0 μg groups (P <.01). | PMC1358954 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT01717989 | - | Completed | - | - | |
NCT01717989 | - | Completed | - | - | |
NCT01181531 | - | Completed | - | - | |
NCT01181531 | Hyperparathyroidism, Secondary | Phase 4 | Completed | - | - |
NCT00135304 | Secondary Hyperparathyroidism | Phase 4 | Completed | - | - |
NCT00977080 | Chronic Kidney Disease ... More >> Secondary Hyperparathyroidism Hemodialysis Less << | Phase 4 | Completed | - | - |
NCT00977080 | - | Completed | - | - | |
NCT02282813 | Chronic Kidney Disease ... More >> Hyperparathyroidism, Secondary Vitamin D Deficiency Less << | Phase 3 | Completed | - | - |
NCT01799317 | Bone Mineralization Defect | Phase 4 | Unknown | June 2014 | United States, California ... More >> Loma Linda University Recruiting Loma Linda, California, United States, 92354 Contact: Shobbha Sahney, MD 909-558-8242 ssahney@llu.edu Principal Investigator: Shobha Sahney, MD Childrens Hospital Los Angeles Recruiting Los Angeles, California, United States, 90027 Contact: Kevin Lemley, MD 323-361-2295 klemley@chla.usc.edu Principal Investigator: Kevin Lemley, MD Less << |
NCT02282813 | - | Completed | - | - | |
NCT01100723 | - | Completed | - | - | |
NCT01100723 | Secondary Hyperparathyroidism ... More >> Chronic Kidney Disease Less << | Phase 4 | Completed | - | United States, Virginia ... More >> Lynchburg Nephrology Associates, P.L.L.C. Lynchburg, Virginia, United States, 24501 Less << |
NCT00560300 | Secondary Hyperparathyroidism ... More >> Renal Osteodystrophy Less << | Phase 2 | Completed | - | - |
NCT00749736 | Chronic Kidney Disease | Phase 4 | Completed | - | United States, Indiana ... More >> Indiana University School of Medicine Indianapolis, Indiana, United States, 46202 Less << |
NCT00257920 | Chronic Kidney Disease, Stage ... More >>5 Secondary Hyperparathyroidism Less << | Phase 4 | Completed | - | United States, Nebraska ... More >> Bellevue, Nebraska, United States, 68123 Omaha, Nebraska, United States, 68131 Less << |
NCT00257920 | - | Completed | - | - | |
NCT00454350 | Secondary Hyperparathyroidism | Phase 4 | Completed | - | United States, Minnesota ... More >> Minneapolis, Minnesota, United States Less << |
NCT00502268 | Coronary Calcification ... More >> Endstage Renal Disease Parathyroid Hormone Less << | Phase 4 | Withdrawn(study never initiate... More >>d) Less << | - | United States, North Carolina ... More >> Davita East Charlotte Dialysis Unit Charlotte, North Carolina, United States, 28208 Less << |
NCT00463021 | Secondary Hyperparathyroidism | Phase 4 | Completed | - | United States, California ... More >> Downey, California, United States Paramount, California, United States United States, Florida Hudson, Florida, United States United States, Georgia Augusta, Georgia, United States Decatur, Georgia, United States United States, Pennsylvania Pittsburgh, Pennsylvania, United States United States, Tennessee Nashville, Tennessee, United States United States, Virginia Norfolk, Virginia, United States Less << |
NCT00123461 | Secondary Hyperparathyroidism ... More >> Renal Failure Chronic Renal Insufficiency Less << | Phase 4 | Completed | - | United States, Arizona ... More >> AKDHC Medical Research Services Phoenix, Arizona, United States, 85012 United States, California UCLA Diabetes Reseach Center Alhambra, California, United States Apex Research of Riverside Riverside, California, United States, 92501 United States, District of Columbia George Washington University Hospital Washington, District of Columbia, United States, 20037 United States, Florida Discovery Medical Research Group Ocala, Florida, United States, 34471 Nephrology Associates Palm Beach Gardens, Florida, United States, 33410 United States, Georgia Georgia Kidney Associates, Inc. Marietta, Georgia, United States, 30060 United States, Michigan Michigan Kidney Consultants, P.C. Pontiac, Michigan, United States, 48341 United States, Minnesota Twin Cities Clinical Research Brooklyn Center, Minnesota, United States, 55430 United States, New York Montefiore Medical Center Bronx, New York, United States University of Rochester Medical Center Rochester, New York, United States, 14642 United States, North Carolina Wake Nephrology Associates, PA Raleigh, North Carolina, United States Wake Forest University School of Medicine Winston-Salem, North Carolina, United States United States, North Dakota Altru Health System Research Center Grand Forks, North Dakota, United States, 58201 United States, Pennsylvania DaVita Lewiston Dialysis Center Lewiston, Pennsylvania, United States, 17044 Temple University Philadelphia, Pennsylvania, United States United States, Virginia Virginia Commonwealth University Richmond, Virginia, United States Puerto Rico Instituto Renal del Este Caguas, Puerto Rico, 00725 Jose Cangiano, MD San Juan, Puerto Rico, 00918 Less << |
NCT00646282 | Hyperparathyroidism, Secondary | Phase 4 | Terminated(slow enrollment and... More >> discontinued once original principal investigator left Emory) Less << | - | United States, Georgia ... More >> Emory University Atlanta, Georgia, United States, 30322 Less << |
NCT00528788 | - | Completed | - | - | |
NCT00528788 | Hyperparathyroidism, Secondary... More >> Kidney Failure, Chronic Less << | Phase 4 | Completed | - | United States, North Carolina ... More >> Duke University Medical Center Dialysis Unit Durham, North Carolina, United States, 27705 Less << |
NCT00022412 | Prostate Cancer | Phase 2 | Completed | - | United States, Iowa ... More >> Holden Comprehensive Cancer Center at University of Iowa Iowa City, Iowa, United States, 52242-1002 United States, New York James P. Wilmot Cancer Center at University of Rochester Medical Center Rochester, New York, United States, 14642 United States, Wisconsin Veterans Affairs Medical Center - Madison Madison, Wisconsin, United States, 53705 Meriter Hospital Madison, Wisconsin, United States, 53715 University of Wisconsin Comprehensive Cancer Center Madison, Wisconsin, United States, 53792-6164 Medical College of Wisconsin Cancer Center Milwaukee, Wisconsin, United States, 53226-3596 Less << |
NCT00052832 | Leukemia Myel... More >>odysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases Less << | Phase 2 | Completed | - | United States, Wisconsin ... More >> University of Wisconsin Comprehensive Cancer Center Madison, Wisconsin, United States, 53792 Less << |
NCT00285467 | Renal Osteodystrophy | Not Applicable | Completed | - | United States, Indiana ... More >> Indiana University School of Medicine Indianapolis, Indiana, United States, 46202 Less << |
NCT00582582 | Prostate Cancer | Phase 2 | Terminated(Lack of drug supply... More >> for doxercalciferol for this study) Less << | - | United States, Wisconsin ... More >> University of Wisconsin Madison, Wisconsin, United States, 53792-5669 Less << |
NCT00511017 | Solid Tumors | PHASE1 | TERMINATED | 2025-09-10 | UT MD Anderson Cancer Center, ... More >>Houston, Texas, 77030, United States Less << |
NCT00646282 | - | Terminated(slow enrollment and... More >> discontinued once original principal investigator left Emory) Less << | - | - | |
NCT00285467 | - | Completed | - | - | |
NCT00601107 | Moderate to Severe Chronic Pla... More >>que Psoriasis Less << | Phase 2 | Completed | - | - |
NCT00889629 | Chronic Kidney Disease ... More >> Kidney Transplantation Less << | Phase 4 | Unknown | January 2010 | United States, New York ... More >> SUNY Downstate Medical Center Recruiting Brooklyn, New York, United States, 11234 Contact: Sima Terebelo, MPH, RPA-C 718-270-8216 Principal Investigator: Mariana Markell, MD Sub-Investigator: Sima Terebelo, MPH, RPA-C Less << |
NCT00418600 | Secondary Hyperparathyroidism | Phase 4 | Completed | - | United States, Arkansas ... More >> Hot Springs, Arkansas, United States United States, California Downey, California, United States Tarzana, California, United States United States, Georgia Atlanta, Georgia, United States United States, Ohio Cincinnati, Ohio, United States United States, Pennsylvania Pittsburgh, Pennsylvania, United States United States, Texas Houston, Texas, United States United States, Washington Spokane, Washington, United States Less << |
NCT00601107 | - | Completed | - | - | |
NCT00792857 | Chronic Kidney Disease ... More >> Secondary Hyperparathyroidism Chronic Renal Insufficiency Chronic Renal Failure Less << | Phase 1 | Completed | - | United States, Arizona ... More >> Pivotal Reseach Centers Peoria, Arizona, United States, 85381 United States, Massachusetts Western New England Renal and Transplant Associates Springfield, Massachusetts, United States, 01107 United States, Ohio University of Cincinnati Cincinnati, Ohio, United States, 45206 United States, Pennsylvania Northeast Clinical Research Allentown, Pennsylvania, United States, 18103-6379 United States, Tennessee Vanderbilt University Nashville, Tennessee, United States, 37232 United States, Texas Southwest Houston Research Ltd. Houston, Texas, United States, 77099 Less << |
NCT02859896 | Secondary Hyperparathyroidism-... More >>Chronic Kidney Disease Less << | Phase 3 | Recruiting | April 2, 2020 | - |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.42mL 0.48mL 0.24mL |
12.12mL 2.42mL 1.21mL |
24.23mL 4.85mL 2.42mL |
|
Dissolving Methods |
in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:
|